摘要
目的探讨莪棱胶囊联合米非司酮治疗子宫内膜异位症的临床疗效。方法选择该院收治的子宫内膜异位症患者60例,分为观察组和对照组各30例。观察组采用米非司酮联合莪棱胶囊治疗,对照组服用米非司酮。比较两组患者的临床有效性,检测血清糖类抗原(CA)125、白细胞介素(IL)-6、可溶性细胞间黏附分子-1(sICAM-1)及基质金属蛋白酶-9(MMP-9)水平。结果观察组患者的总有效率为96.67%,明显高于对照组的86.67%,差异有统计学意义(P<0.05)。治疗后,观察组患者的CA125、MMP-9、IL-6水平均明显低于治疗前和对照组,但sICAM-1水平高于对照组,差异有统计学意义(P<0.05)。观察组胃肠道不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论莪棱胶囊联合米非司酮可作为腹腔镜手术治疗子宫内膜异位症的辅助性措施。
Objective To investigate the efficacy of Eleng Capsule combined with mifepristone in the treatment of endometriosis.Methods Sixty patients with endometriosis treated in our hospital were divided into the observation group and control group,30 cases in each group.The observation group adopted mifepristone combined with Eleng capsule and the control group took mifepristone.The clinical efficacies were compared between the two groups.Serum CA125,IL-6,sICAM-1 and MMP-9 levels were detected.Results The total effective rate of the observation group was significantly higher than that of the control group（96.67% vs.86.67%,P0.05）.The postoperative levels of CA125,MMP-9 and IL-6 in the observation group were significantly lower than those before treatment and in the control group,but the sICAM-1 level was higher than that in the control group,the difference was statistically significant（P0.05）.The gastrointestinal adverse reactions rate in the observation group was lower than that in the control group with statistical difference（P0.05）.Conclusion Eleng Capsule combined with mifepristone can be used as an adjunctive measure for laparoscopic surgery in treating endometriosis.
出处
《检验医学与临床》
CAS
2017年第17期2560-2561,2564,共3页
Laboratory Medicine and Clinic
